Picks for 2026-08-28

1. GLUEMonte Rosa Therapeutics, Inc.

   GLUE, or Monte Rosa Therapeutics, is experiencing a downturn after announcing on August 24th that the first patient was dosed in its Phase 2 clinical trial for MRT-2359, a prostate cancer treatment. Despite this being a development milestone, the market reacted negatively, with the stock declining 3.67% on the day of the announcement and continuing a broader downward trend seen over the last 30 to 90 days. This negative sentiment is further compounded by the company missing analyst estimates for its Q2 2026 earnings, reported on August 6th.

   5-day return +3.44% · +3.33% vs SPY · beat SPY

2. LINLinde plc

   Linde PLC's stock is reacting to its Q2 2026 earnings report from July 31st, where the company beat EPS expectations by a penny but saw its stock fall 6% due to a modest increase in full-year guidance that still fell short of consensus estimates. This suggests investor sensitivity to margin pressure despite strong sales growth, with the stock currently trading near support levels.

   5-day return -2.44% · -2.55% vs SPY · lagged SPY

3. GEGE Aerospace

   GE's stock is reacting to a mix of recent news, primarily its strong Q2 earnings reported on July 16th, where it beat EPS and revenue estimates and raised its full-year guidance for both EPS and free cash flow. This positive financial performance is further supported by GE Vernova's August 24th announcement of a new medium-voltage uninterruptible power supply (MV-UPS) aimed at AI factories and energy-intensive industries, signaling future growth in a high-demand sector. While the stock has seen a significant run-up since May, some analysts are noting it appears fully valued, suggesting the recent "Golden Cross" technical signal, where a short-term moving average crosses above a longer-term one, might be confirming an already priced-in bullish trend.

   5-day return -1.59% · -1.70% vs SPY · lagged SPY

Share this briefing

All published briefings · Full scoreboard · Today's live board